Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Commodity Chemicals
- Sub-Industry: N/A
- Symbol: NASDAQ:ENZY
- CUSIP: N/A
- Web: www.enzymotec.com
- Market Cap: $263.34 million
- Outstanding Shares: 22,949,000
- 50 Day Moving Avg: $10.87
- 200 Day Moving Avg: $8.95
- 52 Week Range: $5.20 - $12.35
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 51.14
- P/E Growth: 4.66
- Annual Revenue: $47.01 million
- Price / Sales: 5.49
- Book Value: $5.90 per share
- Price / Book: 1.91
- EBIDTA: ($4,560,000.00)
- Net Margins: -14.52%
- Return on Equity: -3.88%
- Return on Assets: -3.58%
- Current Ratio: 6.85%
- Quick Ratio: 4.72%
- Average Volume: 81,966 shs.
- Beta: 1.24
- Short Ratio: 1.26
Frequently Asked Questions for Enzymotec (NASDAQ:ENZY)
What is Enzymotec's stock symbol?
Enzymotec trades on the NASDAQ under the ticker symbol "ENZY."
How were Enzymotec's earnings last quarter?
Enzymotec Ltd. (NASDAQ:ENZY) released its earnings results on Wednesday, August, 16th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.05 by $0.15. The business had revenue of $13 million for the quarter, compared to analysts' expectations of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The business's quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.04 earnings per share. View Enzymotec's Earnings History.
When will Enzymotec make its next earnings announcement?
Where is Enzymotec's stock going? Where will Enzymotec's stock price be in 2017?
2 brokerages have issued 1-year price targets for Enzymotec's stock. Their predictions range from $8.00 to $8.00. On average, they expect Enzymotec's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Enzymotec.
What are analysts saying about Enzymotec stock?
Here are some recent quotes from research analysts about Enzymotec stock:
- 1. According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (5/22/2017)
- 2. Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)
Who are some of Enzymotec's key competitors?
Some companies that are related to Enzymotec include RadNet (RDNT), Aurinia Pharmaceuticals (AUPH), Lion Biotechnologies (IOVA), Invacare Corporation (IVC), Karyopharm Therapeutics (KPTI), Achillion Pharmaceuticals (ACHN), PDL BioPharma (PDLI), CLEMENTIA PHARM (CMTA), Progenics Pharmaceuticals (PGNX), Enzo Biochem (ENZ), Jounce Therapeutics (JNCE), Celyad SA (CYAD), Capital Senior Living Corporation (CSU), Surgery Partners (SGRY), Adamas Pharmaceuticals (ADMS), Atara Biotherapeutics (ATRA), NantKwest (NK) and American Renal Associates Holdings (ARA).
Who are Enzymotec's key executives?
Enzymotec's management team includes the folowing people:
- Steve Dubin, Independent Chairman of the Board
- Erez Israeli, President, Chief Executive Officer
- Yoav Doppelt, Independent Vice Chairman of the Board
- Dror Israel, Chief Financial Officer, Vice President
- Yoav Kahane, Chairman of Advanced Lipids AB
- Yoni Twito, Chief Operating Officer
- Naama Zamir, Vice President - Human Resources and Information Systems
- Gai Ben-Dror, Vice President - Process Development
- Tzafra Cohen, Vice President - Research & Development
- Tamar D. Howson, Director
Who owns Enzymotec stock?
Enzymotec's stock is owned by a number of of institutional and retail investors. Top institutional investors include
BERESHEIT GENERAL PARTNER LTD.
(6.10%) and Janus Henderson Group PLC (1.27%). View Institutional Ownership Trends for Enzymotec.
Who sold Enzymotec stock? Who is selling Enzymotec stock?
Enzymotec's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Laurion Capital Management LP, Menta Capital LLC, Public Employees Retirement System of Ohio and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Enzymotec.
Who bought Enzymotec stock? Who is buying Enzymotec stock?
How do I buy Enzymotec stock?
Shares of Enzymotec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzymotec's stock price today?
MarketBeat Community Rating for Enzymotec (NASDAQ ENZY)MarketBeat's community ratings are surveys of what our community members think about Enzymotec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Enzymotec stock can currently be purchased for approximately $11.25.
Consensus Ratings for Enzymotec (NASDAQ:ENZY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$8.00 (28.89% downside)|
Analysts' Ratings History for Enzymotec (NASDAQ:ENZY)
(Data available from 9/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|2/23/2017||Jefferies Group LLC||Reiterated Rating||Hold||$8.00||N/A|
|11/17/2016||Wells Fargo & Company||Downgrade||Outperform -> Market Perform||N/A|
|4/17/2016||Canaccord Genuity||Reiterated Rating||Hold||N/A|
Earnings History for Enzymotec (NASDAQ:ENZY)Earnings History by Quarter for Enzymotec (NASDAQ ENZY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/16/2017||6/30/2017||$0.05||($0.10)||$12.78 million||$13.00 million||View||N/A|
|5/17/2017||3/31/2017||$0.06||$0.03||$14.23 million||$12.00 million||View||N/A|
|2/22/2017||Q416||$0.03||($0.10)||$11.47 million||$10.60 million||View||N/A|
|11/16/2016||Q316||$0.07||$0.03||$13.29 million||$11.40 million||View||N/A|
|8/9/2016||Q216||$0.08||$0.04||$14.90 million||$15.00 million||View||N/A|
|5/19/2016||Q116||$0.05||$0.09||$13.85 million||$14.00 million||View||Listen|
|2/17/2016||Q415||$0.10||$0.07||$14.01 million||$13.30 million||View||Listen|
|11/11/2015||Q315||$0.07||$0.08||$14.21 million||$12.40 million||View||Listen|
|8/12/2015||Q215||$0.06||$0.11||$12.39 million||$13.40 million||View||Listen|
|5/7/2015||Q115||$0.06||$0.09||$12.10 million||$12.25 million||View||N/A|
|2/18/2015||Q414||$0.08||$0.06||$11.11 million||$10.80 million||View||N/A|
|11/13/2014||Q314||$0.04||$0.05||$10.22 million||$9.50 million||View||N/A|
|8/5/2014||Q214||$0.10||$0.02||$14.88 million||$11.50 million||View||N/A|
|5/14/2014||Q114||$0.17||$0.24||$19.40 million||$23.70 million||View||N/A|
|2/13/2014||Q413||$0.11||$0.15||$11.64 million||$18.51 million||View||N/A|
|11/11/2013||Q313||$0.11||$0.13||$13.10 million||$22.50 million||View||Listen|
Earnings Estimates for Enzymotec (NASDAQ:ENZY)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Enzymotec (NASDAQ:ENZY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Enzymotec (NASDAQ:ENZY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Enzymotec (NASDAQ:ENZY)
Latest Headlines for Enzymotec (NASDAQ:ENZY)
Enzymotec (ENZY) Chart for Wednesday, September, 20, 2017